



SOP 410 Appendix 2 Agenda for Site Initiation

Agenda for Site Initiation	
Protocol Title	
Protocol Number / EudraCT reference	
IRAS	
Local reference	
Principal Investigator	
Meeting Date / Start Time	

Attendees		
Name	Role / Title	Representing

	Topic	Presenter	Duration
1	Welcome and Opening Comments: 1.1 Statement of visit objectives 1.2 Review of agenda		
2	Introductions & Roles and Responsibilities <i>(Consider using the Delegation of Responsibilities Log to guide some of the introductions.)</i>		
3	Investigator Responsibilities 3.1 Good Clinical Practice (GCP) 3.2 Records Retention		
4	Protocol Overview 4.1 Type of study 4.2 Study objectives 4.3 Enrolment 4.3.1 Recruitment Screening/Consort targets 4.3.2 Plans for reporting recruitment 4.4 Informed Consent Discussion 4.5 Key inclusion/exclusion criteria 4.6 Study visit schedule/schedule of events		
5	SOPs and Study Procedures 5.1 Review / Patient pathway 5.2 Discussion of procedure for handling updates to study specific SOPs; Working Practice documents and other study specific information		
6	Safety: Definitions, Collection, and Reporting 6.1 Adverse Events (AEs) 6.2 Serious AEs (SAEs) 6.3 Unanticipated Problems: Urgent safety measures and protocol violations 6.4 Queries resulting from the above		
7	Data Collection/Source Documentation 7.1 Paper or Electronic Data Capture (eDC) CRF discussion 7.2 Source Documents (definitions of and retention of) 7.3 Query process, Data query form (template)		



8	<p>Investigational Product (if applicable)</p> <ul style="list-style-type: none"> 8.1 Description of Product 8.2 Review of Investigator Brochure (IB) or SmPC (if applicable), Reference Safety Information (RSI) 8.3 Storage 8.4 Dosing Instructions 8.5 Dispensing 8.6 Accountability 8.7 Return/Destruction Considerations 8.8 Authorisation of release 		
9	<p>Specimen Processing (if applicable)</p> <ul style="list-style-type: none"> 9.1 Collection 9.2 Storage 9.3 Transport 		
10	<p>Clinical Monitoring</p> <ul style="list-style-type: none"> 10.1 Contacts 10.2 Responsibilities of 10.3 Frequency (to be discussed and confirmed after site visit) 10.4 Close out procedures (see SOP 335) 		
11	<p>Investigator Site File Review</p> <ul style="list-style-type: none"> 11.1 Structure of the File as well as Essential Documents to include- Ethics approval, NHS permission, MHRA authorisations (See SOP 305) 		
12	Tour of Facilities (if appropriate)		
13	Closing/Review of Action Items		